Clinical Trial Update: Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update on a dual-target BCMA-GPRC5D CAR-T cell therapy for relapsed or refractory multiple myeloma with extramedullary involvement.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• BCMA-GPRC5D dual-target CAR-T cell therapy

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | Status: RECRUITING